Neurocognition and social cognition in remitted first-episode schizophrenia: correlation with VEGF serum levels

Zhao, Youwei; Xiao, Wenhuan; Chen, Kuan‐Yu; Zhan, Qiongqiong; Ye, Fei; Tang, Xiaowei; Zhang, Xiaobin

doi:10.1186/s12888-019-2397-8

Cited by 13 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VEGF may be involved in the mechanisms underlying cognitive function in patients with remitting schizophrenia, although the mechanism of this relationship remains poorly understood. The authors believe that VEGF may serve as a sensitive monitor for assessing the degree of cognitive impairment and clinical prognosis in schizophrenia [115].…”

Section: Schizophreniamentioning

confidence: 99%

“…VEGF is also involved as a neurotrophic factor in brain homeostasis [114]. Impaired VEGF expression may underlie the hypoperfusion or decreased blood flow observed in patients with schizophrenia [115]. VEGF modulates hippocampal synaptic plasticity associated with memory function [116,117].…”

Section: Schizophreniamentioning

confidence: 99%

“…Levels of VEGF, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) are associated with aging and neurodegeneration [119]. VEGF is an important factor in preventing cognitive decline in neuropsychiatric diseases [115]. ICAM-1 and VCAM-1 are markers of endothelial cell activation.…”

Section: And Alzheimer's Diseasementioning

confidence: 99%

See 2 more Smart Citations

Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders

Morozova

Zorkina

Abramova

et al. 2022

IJMS

View full text Add to dashboard Cite

This review is focused on several psychiatric disorders in which cognitive impairment is a major component of the disease, influencing life quality. There are plenty of data proving that cognitive impairment accompanies and even underlies some psychiatric disorders. In addition, sources provide information on the biological background of cognitive problems associated with mental illness. This scientific review aims to summarize the current knowledge about neurobiological mechanisms of cognitive impairment in people with schizophrenia, depression, mild cognitive impairment and dementia (including Alzheimer’s disease).The review provides data about the prevalence of cognitive impairment in people with mental illness and associated biological markers.

show abstract

Section: Schizophreniamentioning

confidence: 99%

Section: Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders

Morozova

Zorkina

Abramova

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Низкий уровень VEGF, ассоциированный с нарушением ангиогенеза и перфузии нервной ткани, может индуцировать нейродегенерацию [31]. Снижение уровня VEGF по мере утяжеления когнитивных нарушений продемонстрировано также при шизофрении [45].…”

Section: таблица 2 динамика сывороточного уровня цитокинов в зависимости от клинического ответа на терапиюunclassified

Therapeutic effect of soluble factors of M2 phenotype macrophages in children with language impairments

Shevela

Degtyareva²,

Sosnovskaya³

et al. 2021

Med. immunol.

View full text Add to dashboard Cite

The aim of the present study was to assess safety and clinical efficacy of inhalation immunotherapy based on intranasal administration of bioactive factors produced by the M2 phenotype macrophages in children with language impairments, as well as to study the effect of inhalation immunotherapy on the cytokine profile in the patients' blood serum. The study was carried out according to the NCT04689282 protocol (www.ClinicalTrials.gov) and included 14 children (9 boys / 5 girls), aged 3 to 8 years, with language impairments associated with perinatal or postnatal CNS lesions of various origin. The children recruited into the study were assessed by a neurologist and speech therapist before the therapy, at the end of the course (1 month), and 6 months later. Serum samples for cytokine analysis were obtained before and 1 month after therapy. The course of intranasal inhalations by the conditioned M2 media (2 ml one time per day for 28-30 days) was safe and well tolerated. None of the 14 treated children had significant adverse reactions and severe undesirable events. Intranasal immunotherapy led to a decrease in the severity of language problems, which manifested by improved speech understanding by 45%; the sensorimotor level of speech, by 51%; word formation skills, by 72%, as well as a twofold increase in general and fine motor skills. In children with signs of autism spectrum disorders, along with a language improvement, a decrease in the severity of autistic symptoms was registered, as evidenced by statistically significant decrease in the CARS score from 42.5 to 38.5 after 1 month, and to 33 points after 6 months (p < 0.05). The clinical effect was revealed rather soon, i.e., within a month after the first procedure, being maintained or intensified during a follow-up for 6 months. At the same time, two-thirds of the children showed a clear clinical improvement, with insignificant effect in the rest of patients. Comparative analysis of the serum cytokine levels in these subgroups showed that children with a pronounced positive response to inhaled immunotherapy differed in the following parameters: (1) initially higher level of VEGF and IGF-1, and (2) decrease the level of TNFα in response to intranasal immunotherapy. In summary, we first tested a fundamentally new approach based on the use of soluble factors from M2-type macrophages and intranasal route of their administration in order to treat the children with severe language impairments, demonstrating safety and obtained preliminary data on effectiveness of such approach.

show abstract

“…Although symptoms like delusions and hallucinations are reduced in remission stage, the functional recovery are usually not optimistic. Impairment of cognitive functions still existed in schizophrenia patients in remission stage (7) and disability of schizophrenia is largely due to cognitive de cits in this stage (8).…”

Section: Introductionmentioning

confidence: 99%

Effect of virtual reality on cognitive impairment and clinical symptoms among patients with schizophrenia in the remission stage ： a randomized controlled trial

Sun²,

Wei

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This is an intervention study which explores the effect of using virtual reality supermarket training system (VRSTS) to improve cognitive function deficiency and clinical symptoms in Han Chinese patients with schizophrenia in the remission stage. Methods: 68 patients with schizophrenia in the remission stage were recruited for the interventional study and were randomly allocated to either virtual reality training (VRT) group or treatment-as-usual (TAU) group. For VRT group, patients received training with VRSTS for two weeks and antipsychotic treatment as usual while TAU group only received antipsychotic treatment as usual. Cognitive function and clinical symptoms before and after intervention were assessed by MATRICS Consensus Cognitive Battery (MCCB), Positive and Negative Syndrome Scale (PANSS), and the Personal and Social Performance Scale (PSP). Results: Results showed (1) VRSTS could improve MCCB composite scores and 4 out of 7 cognitive domains: speed of processing, working memory, visual learning, reasoning and problem solving, and (2) VRSTS could alleviate general psychopathology symptoms of PANSS but did not exert effects on positive and negative symptoms among patients with schizophrenia in the remission stage Conclusion: A therapeutic effect of VRSTS was observed in patients with schizophrenia in the remission stage. It may improve cognitive impairment and general psychopathology symptoms.

show abstract

Neurocognition and social cognition in remitted first-episode schizophrenia: correlation with VEGF serum levels

Cited by 13 publications

References 54 publications

Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders

Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders

Therapeutic effect of soluble factors of M2 phenotype macrophages in children with language impairments

Effect of virtual reality on cognitive impairment and clinical symptoms among patients with schizophrenia in the remission stage ： a randomized controlled trial

Contact Info

Product

Resources

About